Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)

NCT05021016 is registered in ClinicalTrials.gov with Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" as lead sponsor.

NCT NCT05021016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05021016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)
Lead sponsor
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Phase
Phase 3
Overall status
Completed
Start date
November 19, 2020
Completion date
January 30, 2021
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19